Price Alert

Teva Pharmaceutical Indus... (TEVA)

NYSE: TEVA · Real-Time Price · USD

18.95

0.47 (2.54%)

At close: Sep 05, 2025, 3:59 PM

18.90

-0.26%

After-hours: Sep 05, 2025, 05:17 PM EDT

2.54% (1D)

Bid	18.6
Market Cap	21.74B
Revenue (ttm)	16.63B
Net Income (ttm)	-158M
EPS (ttm)	-0.15
PE Ratio (ttm)	-126.33
Forward PE	6.85
Analyst	Buy

Ask	18.95
Volume	7,331,459
Avg. Volume (20D)	11,195,550
Open	18.48
Previous Close	18.48
Day's Range	18.46 - 18.95
52-Week Range	12.47 - 22.80
Beta	0.72

About TEVA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TEVA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TEVA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Teva Pharmaceutical Industries Limited is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+1.75%

Shares of several biotechnology stocks are trading... Unlock content with Pro Subscription

3 months ago

+4.42%

Teva Pharmaceutical Industries shares are trading higher after the company along with Biolojic Design initiated IND-enabling studies of BD9.

News

7 hours ago · reuters.com

Colorado must face Teva's lawsuit over free allergy pen law

Colorado must face Teva Pharmaceutical Industries' lawsuit challenging a state law requiring it to provide free generic EpiPens to pharmacies, a federal appeals court said Friday.

23 hours ago · zacks.com

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.

1 week ago · reuters.com

US FDA approves Teva Pharmaceuticals' generic obesity drug

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

1 week ago · seekingalpha.com

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Teva offers strong value upside through disciplined execution and does not require growth surprise. Innovative drugs like Austedo have generated consistent revenue growth in the past three years, and ...

2 weeks ago · fool.com

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

Data is the fuel that powers Wall Street. Unfortunately, the amount of data investors have to digest can sometimes be overwhelming.

2 weeks ago · businesswire.com

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.

1 month ago · reuters.com

US FDA approves Teva's Ajovy for migraine prevention in children

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help prevent migraines in children aged six and older who weigh 45 kilograms or...

1 month ago · seekingalpha.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZED...

1 month ago · zacks.com

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.

1 month ago · youtube.com

Teva CEO: Our supply chain puts us in a strong position

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

Load More News